Hematopoietic SCT in Europe: data and trends in 2011
Standard
Hematopoietic SCT in Europe: data and trends in 2011. / Passweg, J R; Baldomero, H; Bregni, M; Cesaro, S; Dreger, P; Duarte, R F; Falkenburg, J H F; Kröger, N; Farge-Bancel, D; Gaspar, H Bobby; Marsh, J; Mohty, M; Peters, C; Sureda, A; Velardi, A; Ruiz de Elvira, C; Madrigal, A; European Group for Blood and Marrow Transplantation.
In: BONE MARROW TRANSPL, Vol. 48, No. 9, 01.09.2013, p. 1161-7.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Hematopoietic SCT in Europe: data and trends in 2011
AU - Passweg, J R
AU - Baldomero, H
AU - Bregni, M
AU - Cesaro, S
AU - Dreger, P
AU - Duarte, R F
AU - Falkenburg, J H F
AU - Kröger, N
AU - Farge-Bancel, D
AU - Gaspar, H Bobby
AU - Marsh, J
AU - Mohty, M
AU - Peters, C
AU - Sureda, A
AU - Velardi, A
AU - Ruiz de Elvira, C
AU - Madrigal, A
AU - European Group for Blood and Marrow Transplantation
PY - 2013/9/1
Y1 - 2013/9/1
N2 - In all, 651 from 680 centers in 48 countries reported 35 660 hematopoietic SCT (HSCT) in 32 075 patients (13 470 allogeneic (42%), 18 605 autologous (58%)) to the 2011 survey. Main indications were: leukemias; 10 113 (32%; 94% allogeneic); lymphoid neoplasias; non-Hodgkin's lymphoma, Hodgkin's lymphoma, plasma cell disorders; 18 433 (57%; 12% allogeneic); solid tumours; 1573 (5%; 5% allogeneic); and non-malignant disorders; 1830 (6%; 92% allogeneic). There were more unrelated donors than HLA identical sibling donors (54% versus 39%); proportion of peripheral blood as stem cell source was 99% for autologous and 73% for allogeneic HSCT. Cord blood was only used in allogeneic transplants (6% of total). In the past 10 years, the overall number of transplants has increased by 53%. Allogeneic HSCT have doubled (from 7272 to 14 549) while, autologous have increased by 32% and continue to increase by about 1100 HSCT per year since 2001. In the past 2 years, an increase of >2000 HSCT per year was seen. Transplant activity is shown by team size. For allogeneic HSCT, we show use of reduced-intensity conditioning versus myeloablative conditioning across Europe and use of post-transplant donor lymphocyte infusions with considerable variation across different countries.
AB - In all, 651 from 680 centers in 48 countries reported 35 660 hematopoietic SCT (HSCT) in 32 075 patients (13 470 allogeneic (42%), 18 605 autologous (58%)) to the 2011 survey. Main indications were: leukemias; 10 113 (32%; 94% allogeneic); lymphoid neoplasias; non-Hodgkin's lymphoma, Hodgkin's lymphoma, plasma cell disorders; 18 433 (57%; 12% allogeneic); solid tumours; 1573 (5%; 5% allogeneic); and non-malignant disorders; 1830 (6%; 92% allogeneic). There were more unrelated donors than HLA identical sibling donors (54% versus 39%); proportion of peripheral blood as stem cell source was 99% for autologous and 73% for allogeneic HSCT. Cord blood was only used in allogeneic transplants (6% of total). In the past 10 years, the overall number of transplants has increased by 53%. Allogeneic HSCT have doubled (from 7272 to 14 549) while, autologous have increased by 32% and continue to increase by about 1100 HSCT per year since 2001. In the past 2 years, an increase of >2000 HSCT per year was seen. Transplant activity is shown by team size. For allogeneic HSCT, we show use of reduced-intensity conditioning versus myeloablative conditioning across Europe and use of post-transplant donor lymphocyte infusions with considerable variation across different countries.
KW - Europe
KW - Hematopoietic Stem Cell Transplantation
KW - History, 21st Century
KW - Humans
KW - Transplantation, Autologous
KW - Transplantation, Homologous
U2 - 10.1038/bmt.2013.51
DO - 10.1038/bmt.2013.51
M3 - SCORING: Journal article
C2 - 23584439
VL - 48
SP - 1161
EP - 1167
JO - BONE MARROW TRANSPL
JF - BONE MARROW TRANSPL
SN - 0268-3369
IS - 9
ER -
